Product Data Sheet

Tubulin inhibitor 14

Cat. No.: HY-145820 CAS No.: 2767446-34-2 Molecular Formula: C₁₅H₉F₂NO Molecular Weight: 257.23

Target: Apoptosis; Microtubule/Tubulin

Pathway: Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	Tubulin inhibitor 14 is a potent NQO2 (quinone oxidoreductase 2) inhibitor with an IC ₅₀ of 1.0 μM. Tubulin inhibitor 14 also
	inhibits tubulin polymerization and the formation of endothelial cell capillary-like tubes. Tubulin inhibitor 14 is a
	$microtubule-destabilizing\ agent\ with\ potential\ tumor-selectivity\ and\ antiangiogenic\ and\ vascular\ disrupting\ features^{[1]}.$

IC₅₀: 1.0 μ M (NQO2)^[1]. IC₅₀ & Target

In Vitro Tubulin inhibitor 14 (compound 4) (0-20 μ M, 96 h) inhibits cancer cells proliferation [1].

> Tubulin inhibitor 14 (1-5 μ M, 24 or 48 h) causes G2/M cell cycle arrest^[1]. Tubulin inhibitor 14 (0.5-1 μM, 24 h) induces SNU423 cell apoptosis^[1].

Tubulin inhibitor 14 (0.5-1 μ M, 24 h) disrupts the cytoskeleton network in endothelial cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	MDA-MB-231, HepG2, SNU423, A549, HCT116
Concentration:	0 μM, 0.1 μM, 0.5 μM, 1 μM, 5 μM, 10 μM, and 20 μM
Incubation Time:	96 h
Result:	Inhibited cell proliferation with IC $_{50}$ values of 0.41 μ M (MCF-7) , 0.07 μ M (MDA-MB-231), 1.44 μ M (HepG2), 0.25 μ M (SNU423), 0.27 μ M (A549), and 0.13 μ M (HCT116).
Cell Cycle Analysis ^[1]	

Cell Line:	HepG2 cells
Concentration:	1, 2, 5 μΜ
Incubation Time:	24 h, 48 h
Result:	Caused G2/M cell cycle arrest.

Apoptosis Analysis^[1]

Cell Line: SNU423 cells

Concentration:	0.5, 1 μΜ
Incubation Time:	24 h
Result:	Induced SNU423 cell apoptosis.
Immunofluorescence ^[1]	
Cell Line:	HUVECs
Concentration:	0.5, 1 μΜ
Incubation Time:	24 h
Result:	Disrupted the cytoskeleton network in endothelial cells.

REFERENCES

[1]. Mai A. Elhemely, et al. SAR of Novel 3-Arylisoquinolinones: meta-Substitution on the Aryl Ring Dramatically Enhances Antiproliferative Activity through Binding to Microtubules. J Med Chem. 2022 Mar 24;65(6):4783-4797.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA